![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » AVANIR Acquires Additional Rights to IriSys' Neurodex Technology
AVANIR Acquires Additional Rights to IriSys' Neurodex Technology
AVANIR Pharmaceuticals has announced that, through a wholly owned subsidiary, it has acquired from IriSys, additional rights to Neurodex, AVANIR's late-stage drug candidate for the treatment of multiple central nervous system disorders, which was sublicensed from IriSys in 2000. As a result, AVANIR, through its subsidiary, holds the exclusive worldwide marketing rights to Neurodex for five indications under a royalty-bearing license with the owner of the underlying technology, The Center for Neurologic Study.
BioSpace (http://www.biospace.com/news_story.cfm?StoryID=19319320&full=1)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct